EICHORCondition: Diabetes · Sponsor: Mostafa Bahaa
Interested? Contact the study team ↓
Type 1 Diabetes (T1DM) is a disease characterised by immune mediated destruction of the insulin-producing pancreatic beta cells. Overtime, obvious insulin deficiency develops which requires insulin therapy. T1DM accounts for about 5% to 10% of diabetes cases in Europe and United States. Currently, worldwide incidence is estimated to be around 15 per 100,000 people per year. Despite the advancement that has occurred in the field diabetes therapy, patient with T1DM still suffer from managing their disease as well as continuing to face diabetes related complications. The American Diabetes Association (ADA) recommend a goal of glycated haemoglobin (HbA1c) of \< 7%. However, only 21% of adults in the United States has achieved this recommended goal. Once again, a multinational, multicentre study shows that only 24.3% of participants achieved the glycaemic target of HbA1c less than 7.0 %. Unfortunately, intensifying the insulin therapy in order to reach the targeted HbA1c can result in serious adverse effects of hypoglycaemia and weight gain which is in its turn is known risk factor for cardiovascular disease.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * patients diagnosed with type 1 diabetes for more than 1 year. * Age 18-65 years. * BMI ≥ 27 kg/m². * HbA1c 7.5-10 % (58-86 mmol/mol) * Inadequately controlled despite treatment with multiple daily injections of insulin for at least 1 year. Exclusion Criteria: History of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2) syndrome; family history of multiple endocrine neoplasia, type 2A (MEN 2A), medullary thyroid cancer, or familial medullary thyroid cancer. * Insulin pump treatment. * Any prior use of GLP-1 RAs or dipeptidyl peptidase-4 inhibitors, any medication (except insulin) that could interfere with glycemic control or affect a subject's safety. * An estimated glomerular filtration rate ≤ 30 mL/min/1.73 m2. * Liver disease with raised alanine aminotransferase (AST), aspartate transaminase (ALT) or alkaline phosphatase (ALP)more than three times the upper normal range. * History of pancreatitis. * Gastroparesis. * Pregnancy or lactation. * History of alcohol or drug misuse, or any medical or psychological disorder that made the patient unsuitable for study participation. * Acute symptomatic urinary tract infection or genital infection; chronic or recurrent (≥3 annual episodes) cystitis. * Hypoglycaemia that required hospitalization or emergency treatment in the 3 months. * DKA that required hospitalization or emergency treatment in the past 12 months. * Treatment with anti-obesity drugs, weight-loss surgery or aggressive diet regimen leading to unstable body weight (based on Investigator's judgement) for the last 3 months.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Tanta Unuversity | Tanta, Egypt | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06762314